Pharmacokinetics of BIBR 277 in Hypertensive Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Low dose of BIBR 277
Medium dose of BIBR 277
High dose of BIBR 277
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Age: >=20 years
- Sex: Either male or female
- Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
- BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.
Exclusion Criteria:
- Malignant hypertension
- Renovascular hypertension
- Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
- Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
- Symptoms of cerebrovascular disorder
- Serious hepatic dysfunction
- Renal function disorder (serum creatinine >= 4.0 mg/dL)
- Known hypersensitivity to angiotensin II receptor antagonists
- Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L))
- Treatment with the other investigational drug within 6 months of initiation of the present study
- Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
- Previous treatment with the trial medication of the present study
- Otherwise judged ineligible by the investigator
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Low dose of BIBR 277
Medium dose of BIBR 277
High dose of BIBR 277
Arm Description
Outcomes
Primary Outcome Measures
Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)
Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)
Maximum measured concentration of BIBR 277 in plasma (Cmax)
Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)
Terminal elimination half-time of BIBR 277 in plasma (t1/2)
Secondary Outcome Measures
Changes from baseline in blood pressure (systolic, diastolic, and mean)
Changes from baseline in pulse rate
Number of patients with adverse events
Changes from baseline in laboratory test values
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02187497
Brief Title
Pharmacokinetics of BIBR 277 in Hypertensive Patients
Official Title
BIBR 277 Capsules Pharmacokinetics Study of Hypertensive Patients
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
June 1998 (undefined)
Primary Completion Date
September 1998 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives was evaluated. The results of the present study are to be used in the Japanese population pharmacokinetics analysis
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
93 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low dose of BIBR 277
Arm Type
Experimental
Arm Title
Medium dose of BIBR 277
Arm Type
Experimental
Arm Title
High dose of BIBR 277
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Low dose of BIBR 277
Intervention Type
Drug
Intervention Name(s)
Medium dose of BIBR 277
Intervention Type
Drug
Intervention Name(s)
High dose of BIBR 277
Primary Outcome Measure Information:
Title
Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)
Time Frame
Pre-dose up to 24 hours after start of treatment
Title
Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)
Time Frame
Pre-dose up to 24 hours after start of treatment
Title
Maximum measured concentration of BIBR 277 in plasma (Cmax)
Time Frame
Pre-dose up to 24 hours after start of treatment
Title
Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)
Time Frame
Pre-dose up to 24 hours after start of treatment
Title
Terminal elimination half-time of BIBR 277 in plasma (t1/2)
Time Frame
Pre-dose up to 24 hours after start of treatment
Secondary Outcome Measure Information:
Title
Changes from baseline in blood pressure (systolic, diastolic, and mean)
Time Frame
Pre-dose up to 14 days after start of treatment
Title
Changes from baseline in pulse rate
Time Frame
Pre-dose up to 14 days after start of treatment
Title
Number of patients with adverse events
Time Frame
Up to 29 days
Title
Changes from baseline in laboratory test values
Time Frame
Pre-dose up to 14 days after start of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: >=20 years
Sex: Either male or female
Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.
Exclusion Criteria:
Malignant hypertension
Renovascular hypertension
Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
Symptoms of cerebrovascular disorder
Serious hepatic dysfunction
Renal function disorder (serum creatinine >= 4.0 mg/dL)
Known hypersensitivity to angiotensin II receptor antagonists
Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L))
Treatment with the other investigational drug within 6 months of initiation of the present study
Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
Previous treatment with the trial medication of the present study
Otherwise judged ineligible by the investigator
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.268_U04-3141.pdf
Description
Related Info
Learn more about this trial
Pharmacokinetics of BIBR 277 in Hypertensive Patients
We'll reach out to this number within 24 hrs